Literature DB >> 21615153

Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens.

Nijaporn Yanasarn1, Brian R Sloat, Zhengrong Cui.   

Abstract

Liposomes have been investigated extensively as a vaccine delivery system. Herein the adjuvant activities of liposomes with different net surface charges (neutral, positive, or negative) were evaluated when admixed with protein antigens, ovalbumin (OVA, pI = 4.7), Bacillus anthracis protective antigen protein (PA, pI = 5.6), or cationized OVA (cOVA). Mice immunized subcutaneously with OVA admixed with different liposomes generated different antibody responses. Interestingly, OVA admixed with net negatively charged liposomes prepared with DOPA was as immunogenic as OVA admixed with positively charged liposomes prepared with DOTAP. Immunization of mice with the anthrax PA protein admixed with the net negatively charged DOPA liposomes also induced a strong and functional anti-PA antibody response. When the cationized OVA was used as a model antigen, liposomes with net neutral, negative, or positive charges showed comparable adjuvant activities. Immunization of mice with the OVA admixed with DOPA liposomes also induced OVA-specific CD8(+) cytotoxic T lymphocyte responses and significantly delayed the growth of OVA-expressing B16-OVA tumors in mice. However, not all net negatively charged liposomes showed a strong adjuvant activity. The adjuvant activity of the negatively charged liposomes may be related to the liposome's ability (i) to upregulate the expression of molecules related to the activation and maturation of antigen-presenting cells and (ii) to slightly facilitate the uptake of the antigens by antigen-presenting cells. Simply admixing certain negatively charged liposomes with certain protein antigens of interest may represent a novel platform for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615153      PMCID: PMC3148289          DOI: 10.1021/mp200016d

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  52 in total

1.  Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.

Authors:  J Hartikka; V Bozoukova; M Ferrari; L Sukhu; J Enas; M Sawdey; M K Wloch; K Tonsky; J Norman; M Manthorpe; C J Wheeler
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

Review 2.  Microparticle-based technologies for vaccines.

Authors:  Derek T O'Hagan; Manmohan Singh; Jeffrey B Ulmer
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

3.  Liposomes as immunological adjuvants.

Authors:  A G Allison; G Gregoriadis
Journal:  Nature       Date:  1974-11-15       Impact factor: 49.962

4.  Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation.

Authors:  P N Shek; B H Sabiston
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

5.  Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.

Authors:  Farhat Afrin; Ravindran Rajesh; Khairul Anam; Meenakshisundram Gopinath; Swati Pal; Nahid Ali
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.

Authors:  F Afrin; N Ali
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

7.  Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.

Authors:  Brian R Sloat; Zhengrong Cui
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

8.  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Authors:  Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

9.  Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.

Authors:  B Guy; N Pascal; A Françon; A Bonnin; S Gimenez; E Lafay-Vialon; E Trannoy; J Haensler
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

10.  Enhancement of IFN-gamma production for Th1-cell therapy using negatively charged liposomes containing phosphatidylserine.

Authors:  Satoshi Yotsumoto; Terutaka Kakiuchi; Yukihiko Aramaki
Journal:  Vaccine       Date:  2007-06-08       Impact factor: 3.641

View more
  13 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis.

Authors:  Weifeng Zhang; Lianyan Wang; Yuan Liu; Xiaoming Chen; Jiahui Li; Tingyuan Yang; Wenqi An; Xiaowei Ma; Ruowen Pan; Guanghui Ma
Journal:  Pharm Res       Date:  2013-10-30       Impact factor: 4.200

Review 3.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

4.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 5.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

6.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

7.  Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.

Authors:  Federico Perche; Rudy Clemençon; Kai Schulze; Thomas Ebensen; Carlos A Guzmán; Chantal Pichon
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-30       Impact factor: 8.886

Review 8.  Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization.

Authors:  Ning Wang; Minnan Chen; Ting Wang
Journal:  J Control Release       Date:  2019-05-03       Impact factor: 9.776

9.  Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.

Authors:  Laleh Naghibi; Mona Yazdani; Amir Abbas Momtazi-Borojeni; Atefeh Razazan; Sheida Shariat; Mercedeh Mansourian; Atefeh Arab; Nastaran Barati; Mahdieh Arabsalmani; Azam Abbasi; Zahra Saberi; Ali Badiee; Seyed Amir Jalali; Mahmoud Reza Jaafari
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

10.  Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes.

Authors:  Christopher B Fox; Sean K Mulligan; Joyce Sung; Quinton M Dowling; H W Millie Fung; Thomas S Vedvick; Rhea N Coler
Journal:  Int J Nanomedicine       Date:  2014-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.